Quantum Biopharma (QNTM) Income from Continuing Operations (2019 - 2026)

Quantum Biopharma has disclosed Income from Continuing Operations across 8 years of filings, most recently posting 2966305.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 2966305.0, up 13.34% year-over-year; the trailing twelve-month figure through Mar 2026 was 15237851.0 (down 15.68% YoY), and the FY2025 annual result was 15460437.0, up 4.38% from the prior year.
• Income from Continuing Operations came in at 2966305.0 for Q1 2026 at Quantum Biopharma, down from 2531448.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 25292797.0 in Q2 2023 to a low of 9845642.0 in Q1 2023.
• The 5-year median for Income from Continuing Operations is 3370402.0 (2023), against an average of 1436463.79.
• Across the five-year window, Income from Continuing Operations plunged 274.88% in 2023 and jumped 76.95% in 2024, its largest moves.
• Quantum Biopharma's Income from Continuing Operations stood at 5630055.0 in 2022, then tumbled by 227.7% to 7189574.0 in 2023, then soared by 70.88% to 2093300.0 in 2024, then slipped by 20.93% to 2531448.0 in 2025, then retreated by 17.18% to 2966305.0 in 2026.
• The last three Income from Continuing Operations figures came in at 2966305.0 (Q1 2026), 2531448.0 (Q4 2025), and 4769697.0 (Q3 2025), per Business Quant data.